GlassScriptPhysician profile
Barjinder Singh
NPI 1114926847
$2,983.52
in general payments reported to CMS, 2019-2025
47 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $483 · 2021: $265 · 2022: $266 · 2023: $221 · 2024: $833 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.26 |
| Education | $102.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.97 | 2019-2025 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $193.21 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $172.80 | 2019-2024 | |
| Pfizer INC. | $168.95 | 2019-2025 | |
| Eisai INC. | $166.02 | 2019-2025 | |
| Janssen Biotech, INC. | $149.22 | 2019-2020 | |
| Genzyme Corporation | $144.95 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $114.90 | 2019-2020 | |
| Amgen INC. | $102.99 | 2019-2024 | Prolia, Evenity |
| Karyopharm Therapeutics INC. | $89.45 | 2024-2025 | Xpovio |
| Dendreon Pharmaceuticals LLC | $89.40 | 2024 | Provenge |
| Array Biopharma INC | $82.34 | 2020-2025 | Xalkori, Braftovi, Lorbrena |
| Incyte Corporation | $80.52 | 2021-2025 | Monjuvi |
| Novocure INC. | $72.29 | 2024 | Optune |
| Sanofi-Aventis U.S. LLC | $71.99 | 2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barjinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.